Aromatase inhibitors (AIs), such as anastrozole and letrozole, block aromatase and interfere with conversion of androgens into estrogens, and form the backbone of treatment for ER + ve BC (Supplementary Fig. 1). Here, CYP19A1 is linked to breast cancer.